Prime Medicine
John R. Hadcock, Ph.D. has extensive work experience in the biotechnology and pharmaceutical industry. John R. currently holds the role of Vice President of Nonclinical Development and Pharmacology at Prime Medicine, Inc. starting from January 2023. Prior to this, they served as the Vice President of Discovery and Non-Clinical Development at Yarrow Biotechnology from August 2021 to January 2023.
Before joining Yarrow Biotechnology, Dr. Hadcock worked at Sarepta Therapeutics as the Executive Director of Translational Sciences, Quantitative Pharmacology, DMPK, and Preclinical Safety from April 2020 to August 2021. John R. also held the position of Senior Director of Quantitative Pharmacology at Sarepta from April 2019 to April 2020.
Dr. Hadcock has also served in leadership roles at Cyclerion and Ironwood Pharmaceuticals, where they worked as the Senior Director of Pharmacology and DMPK. Their work at these companies focused on the soluble guanylate cyclase/cyclic GMP pathway and covered various therapeutic areas ranging from metabolic diseases to CNS disorders.
Earlier in their career, Dr. Hadcock held positions at Novartis Institutes for BioMedical Research, Pfizer, Cardiovascular/Metabolic, Wyeth, and American Cyanamid, where they worked in research and development roles with a focus on cardiovascular, metabolic, and CNS diseases.
Overall, Dr. John R. Hadcock's work experience demonstrates their expertise in drug development and their contributions to the field of pharmacology and preclinical research.
John R. Hadcock, Ph.D. completed their Bachelor of Science degree in Biology, with a focus on Animal Behavior and Zoology, from Long Island University, C.W. Post College, between the years 1977 and 1981. John R. then pursued a Master of Science degree in Cell Biology at LIU Post from 1981 to 1983. Subsequently, they enrolled at Stony Brook University and the State University of New York at Stony Brook School of Medicine, earning their Ph.D. in Pharmacology and Molecular and Cellular Pharmacology respectively, from 1985 to 1989.
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.